CN104825873A - Composition of EGCG and bamboo leaf flavonoid, preparation method and applications thereof - Google Patents
Composition of EGCG and bamboo leaf flavonoid, preparation method and applications thereof Download PDFInfo
- Publication number
- CN104825873A CN104825873A CN201510228678.XA CN201510228678A CN104825873A CN 104825873 A CN104825873 A CN 104825873A CN 201510228678 A CN201510228678 A CN 201510228678A CN 104825873 A CN104825873 A CN 104825873A
- Authority
- CN
- China
- Prior art keywords
- egcg
- folium bambosae
- bambosae flavone
- preparation
- flavone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 216
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 215
- 238000002360 preparation method Methods 0.000 title claims abstract description 203
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 235000017166 Bambusa arundinacea Nutrition 0.000 title abstract 3
- 235000017491 Bambusa tulda Nutrition 0.000 title abstract 3
- 241001330002 Bambuseae Species 0.000 title abstract 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 title abstract 3
- 239000011425 bamboo Substances 0.000 title abstract 3
- 229930003935 flavonoid Natural products 0.000 title abstract 3
- 150000002215 flavonoids Chemical class 0.000 title abstract 3
- 235000017173 flavonoids Nutrition 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 46
- 239000002552 dosage form Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 17
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 17
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 17
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 12
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 344
- 229930003944 flavone Natural products 0.000 claims description 344
- 150000002212 flavone derivatives Chemical class 0.000 claims description 344
- 235000011949 flavones Nutrition 0.000 claims description 344
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 344
- 239000008187 granular material Substances 0.000 claims description 75
- 239000000843 powder Substances 0.000 claims description 49
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 35
- 238000002347 injection Methods 0.000 claims description 35
- 239000007924 injection Substances 0.000 claims description 35
- 229920002472 Starch Polymers 0.000 claims description 33
- 235000019698 starch Nutrition 0.000 claims description 33
- 239000008107 starch Substances 0.000 claims description 33
- 239000002775 capsule Substances 0.000 claims description 30
- 239000002671 adjuvant Substances 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 24
- 235000010355 mannitol Nutrition 0.000 claims description 23
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 21
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000011734 sodium Substances 0.000 claims description 21
- 229910052708 sodium Inorganic materials 0.000 claims description 21
- 239000005715 Fructose Substances 0.000 claims description 18
- 229930091371 Fructose Natural products 0.000 claims description 18
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 18
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 16
- 239000011812 mixed powder Substances 0.000 claims description 16
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 229920000881 Modified starch Polymers 0.000 claims description 15
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 229920001353 Dextrin Polymers 0.000 claims description 14
- 239000004375 Dextrin Substances 0.000 claims description 14
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 14
- 235000019425 dextrin Nutrition 0.000 claims description 14
- 239000006187 pill Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 229920002774 Maltodextrin Polymers 0.000 claims description 13
- 239000005913 Maltodextrin Substances 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 229940035034 maltodextrin Drugs 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 11
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 10
- 229920000377 Sinistrin Polymers 0.000 claims description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 10
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 9
- 210000005013 brain tissue Anatomy 0.000 claims description 9
- 210000005003 heart tissue Anatomy 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 238000005550 wet granulation Methods 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 229920001100 Polydextrose Polymers 0.000 claims description 7
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 7
- 235000013365 dairy product Nutrition 0.000 claims description 7
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 239000001259 polydextrose Substances 0.000 claims description 7
- 235000013856 polydextrose Nutrition 0.000 claims description 7
- 229940035035 polydextrose Drugs 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 7
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 6
- 108010011485 Aspartame Proteins 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 239000004384 Neotame Substances 0.000 claims description 6
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 6
- 239000004383 Steviol glycoside Substances 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 6
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 6
- 229960004998 acesulfame potassium Drugs 0.000 claims description 6
- 239000000619 acesulfame-K Substances 0.000 claims description 6
- 239000000605 aspartame Substances 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- 229960003438 aspartame Drugs 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 235000019412 neotame Nutrition 0.000 claims description 6
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 6
- 108010070257 neotame Proteins 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 6
- 235000019411 steviol glycoside Nutrition 0.000 claims description 6
- 229930182488 steviol glycoside Natural products 0.000 claims description 6
- 150000008144 steviol glycosides Chemical class 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000003889 eye drop Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 10
- 230000002490 cerebral effect Effects 0.000 abstract description 5
- 230000002107 myocardial effect Effects 0.000 abstract description 3
- 208000023516 stroke disease Diseases 0.000 abstract 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 183
- 239000003826 tablet Substances 0.000 description 62
- 235000019658 bitter taste Nutrition 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 15
- 229940023488 pill Drugs 0.000 description 13
- 239000007919 dispersible tablet Substances 0.000 description 12
- 239000007938 effervescent tablet Substances 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000013270 controlled release Methods 0.000 description 9
- 229940100688 oral solution Drugs 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000003708 ampul Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 5
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 5
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 5
- 239000007910 chewable tablet Substances 0.000 description 5
- 229940068682 chewable tablet Drugs 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012925 reference material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 241000745988 Phyllostachys Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000630329 Scomberesox saurus saurus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013064 chemical raw material Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000004073 flavone group Chemical group 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 108010010998 polyactin A Proteins 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition containing EGCG and bamboo leaf flavonoid. The composition can be made into any pharmaceutically-acceptable dosage form, and the weight ratio of EGCG to bamboo leaf flavonoid is 0.05-2:1. The invention further discloses a preparation method of the composition and applications of the composition in preparation of drugs for protecting heart and cerebral vessels and tissues, relieving myocardial and cerebral ischemia, and reducing the happening rate of myocardial infarction, stroke, and cardiovascular diseases.
Description
Technical field
The present invention relates to a kind of healthy product compositions, and its preparation method and application, the specifically compositions of EGCG and Folium Bambosae flavone, with and its preparation method and application.Healthy product compositions of the present invention, includes but not limited to medicine, medical food, health food or functional food, bread and cheese etc.
Background technology
EGCG, i.e. epigallocatechin gallate (EGCG), structural formula is as follows,
,
EGCG is a kind of native compound that extracting and developing obtains from green tea; it is the most efficient active monomer component in tea polyphenols; there is good safety and physiological activity widely; research shows; EGCG has antithrombus formation, arteriosclerosis, neuroprotective system, free radical resisting infringement, antioxidation, anti-oxidation stress, antiangiogenic, immunity moderation, protection cardiovascular and cerebrovascular vessel and antiinflammatory, antitumor, antiviral, antibacterial action, very important for health.
But disadvantageously, on the one hand, EGCG is more single in the mechanism of action for the treatment of cardiac and cerebral vascular diseases, lack the function of omnibearing protection cardiovascular and cerebrovascular vessel or treatment cardiovascular and cerebrovascular disease; On the other hand, the taste of EGCG is very pained, limits its application in medicine food, consumer or patient direct oral time be difficult to accept its bitter taste, the compliance making it apply is seriously restricted.
Folium Bambosae flavone; it is the biological flavone with physiologically active extracted from the Folium Bambusae of grass family Phyllostachys Ph. meyeri; it is a kind of biological anti-oxidant efficiently; it is the nutrient of needed by human; there are protection cardiovascular and cerebrovascular vessel; improve myocardial ischemia, improve cerebral ischemia, adjusting blood lipid; reduce the effect of blood viscosity; there is control cardiovascular and cerebrovascular disease; the function of antioxidation, antiinflammatory and immunity moderation; when human body lacks, easily cause the generation of the diseases such as heart and brain function are incomplete, sclerosis of blood vessels.
Summary of the invention
The discovery that inventor is pleasantly surprised, EGCG and Folium Bambosae flavone are combined, there is good synergism, especially in protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia etc. in synergism, and reducing the effect that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs; On the other hand, Folium Bambosae flavone can improve the bitter taste of EGCG, make consumer or patient direct oral time be easy to accept.
The object of this invention is to provide a kind of pharmaceutical composition containing EGCG and Folium Bambosae flavone, the dosage form of described medicine is any pharmaceutical dosage form of acceptable on pharmaceutics.
Another object of the present invention is to provide the preparation method of above-mentioned composition;
The invention still further relates to the application of above-mentioned composition in medicine, medical usage.
The present composition comprises two kinds of compound modes:
A kind of compound mode is existed with the form of compound preparation EGCG and Folium Bambosae flavone, and the dosage form of described medicine is any pharmaceutical dosage form of acceptable on pharmaceutics.Use corresponding pharmaceutical carrier or adjuvant, adopt different preparation technologies to can be made into different compound medicinal formulations.Be to be understood that, compound preparation refers to makes independent preparation using EGCG and Folium Bambosae flavone as medicament active composition, it can be any pharmaceutical dosage form that pharmaceutics can accept, preferred oral preparation, such as tablet (comprises dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet, Deng), hard capsule (comprising enteric coated capsule), soft capsule, granule, powder, dry suspension, pill, pellet (comprising enteric coated micropill), drop pill, dry syrup, powder, oral solution, oral administration mixed suspension, and oral rapid release or the dosage form such as slow release or controlled release, or injection or cutaneous permeable agent, powder ampoule agent for injection (comprises Injectable sterile fill injectable powder, lyophilized injectable powder), aqueous solution injection, injection can also be with glucose, sodium chloride, fructose, Nulomoline, xylitol or maltose etc. use the aqueous solution of (comprising intravenous injection and intravenous drip) as the intravenous injection of osmotic pressure regulator, also comprise the ointment of external preparation for skin, gel, emulsion agent, emulsion agent, patch, etc., also can be the dosage form such as rapid release, slow release, controlled release of above various dosage form, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, born of the same parents rise granule, etc.Especially, by means known in the art preparation, be preferred for preparing oral solution, tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), injection (comprising powder ampoule agent for injection and injection) that pharmaceutics uses.Preferred combination dosage form is oral formulations, most preferably oral granule, powder, dry suspension, tablet (comprise dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet, etc.), hard capsule (comprising enteric coated capsule), soft capsule, pill, pellet (comprising enteric coated micropill), drop pill, dry syrup, powder, oral solution, oral administration mixed suspension etc.
Another kind of compound mode is that EGCG and Folium Bambosae flavone are made independent preparation respectively, in use, patient can successively medication successively, also use after the preparation of the EGCG separated can being mixed with the preparation of Folium Bambosae flavone simultaneously, finally to reach the object using composition of medicine of the present invention, necessary, two kinds of independent preparations should be packaged in same drug package assembly by conveniently patient medication and represent the feature of drug regimen; Further, when EGCG and Folium Bambosae flavone are independent preparations, both pharmaceutical dosage forms can be identical, also can be different, as EGCG sheet and Folium Bambosae flavone tablet medicament composition, EGCG capsule and Folium Bambosae flavone pharmaceutical capsules compositions, EGCG sheet and Folium Bambosae flavone pharmaceutical capsules compositions, EGCG capsule and Folium Bambosae flavone tablet medicament composition, also can be the dosage form such as rapid release, slow release, controlled release of above various dosage form, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, born of the same parents rise granule, etc.Especially, by means known in the art preparation, be preferred for preparing tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), granule, powder, dry suspension, pill, pellet (comprising enteric coated micropill), drop pill, dry syrup, powder, oral solution, injection (comprising powder ampoule agent for injection and injection) etc. that pharmaceutics uses.
Should be appreciated that or can give the present invention's compound of combination in turn simultaneously, these combination of compounds can be same or different pharmaceutical compositions.If administration in turn, the delay administration of the second active component should not reduce the effect of synergistic therapeutic action between this active ingredient combinations or collaborative drug mechanism.No matter simultaneously or administration in turn it is also understood that, EGCG and Folium Bambosae flavone can with independent or any combining form administrations, preferably by EGCG and Folium Bambosae flavone administration simultaneously or with the administration in turn of independent medicine type, and most preferably administration simultaneously.
Preferably give drug regimen of the present invention with compound preparation form, such as tablet, special in tablet is double-layer tablet, chewable tablet, capsule, granule, powder, dry suspension, oral solution, liquid preparation, medicinal tea for another example, etc.
Especially, the pharmaceutical composition containing EGCG and Folium Bambosae flavone provided by the invention, when pharmaceutical dosage form is the solid preparations such as tablet, capsule, granule, powder or dry suspension, wherein EGCG or Folium Bambosae flavone are the compositionss made with micronized form, preferred EGCG and Folium Bambosae flavone are pulverized by low-temperature airflow crushing technology, its powder size is greater than 800 orders, and preferred powder size is at 800 ~ 1000 orders, and even the granularity of preferred powder is greater than 1000 orders.
The present invention that another aspect of the present invention provides EGCG and Folium Bambosae flavone to exist with the ratio of synergistic drug dose combines.
Another aspect of the present invention provides EGCG and Folium Bambosae flavone with the combination of arbitrary proportion, and preferably with the present invention's combination that the ratio of synergistic dosage exists, EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.2 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.3 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.4 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.5 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.6 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.7 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.8 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1.9) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.15 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1.4) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1.3) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1.2) with weight ratio: the ratio combination of 1;
Concrete, such as preferably EGCG and Folium Bambosae flavone take weight ratio as 0.05:1,0.06:1,0.07:1,0.08:1,0.09:1,0.1:1,0.2:1,0.3:1,0.4:1,0.5:1,0.6:1,0.7:1,0.8:1,0.9:1,1:1,1.1:1,1.2:1,1.3:1,1.4:1,1.5:1,1.6:1,1.7:1,1.8:1,1.9:1,2:1, etc.
The oral applicable dosage of EGCG is generally adult's 50 ~ 1000mg level every day and gives this compound, preferred every day 100 ~ 800mg single or give this compound at twice, such as 100mg, 150mg, 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, the EGCG of 900mg or 1000mg, and give the Folium Bambosae flavone of effective dose, preferably give the Folium Bambosae flavone of 50 ~ 2000mg, such as 50mg, 100mg, 150mg, 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, 850mg, 900mg, 950mg, 1000mg, 1100mg, 1200mg, 1300mg, 1400mg, 1500mg, 1600mg, 1700mg, 1800mg, the Folium Bambosae flavone of 1900mg or 2000mg, etc..
Be to be understood that, the present invention contains the compositions of EGCG and Folium Bambosae flavone, optionally can also contain other medicines effect or food function composition, such as mannatide, lentinan, oligofructose, polyfructosan, oligomeric xylose, Oligomeric manna sugar, etc.
Preferably, the pharmaceutical composition of EGCG and Folium Bambosae flavone, wherein contains 50 ~ 1000mgEGCG and 50 ~ 2000mg Folium Bambosae flavone in preferred per unit preparation;
Concrete, containing 50mgEGCG and 50mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 160mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1100mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1200mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1300mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1400mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1500mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1600mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1700mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1800mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1900mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 2000mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1100mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1200mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1300mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1400mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1500mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1600mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1700mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1800mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1900mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 2000mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1100mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1200mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1300mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1400mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1500mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1600mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1700mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1800mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1900mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 2000mg Folium Bambosae flavone in per unit preparation,
Or containing 350mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 400mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 500mgEGCG and 500mg Folium Bambosae flavone in per unit preparation.
Described " per unit preparation " refers to the preparation unit of minimum package or minimum form of medication, comprise each seed lac wafer, each tablet or pill, each bag of granule or powder, each bottle of oral administration solution, each injection or injection, each bottle of injection or injection, each piece of suppository, each bottle of eye drop, each pipe ointment, etc.
Usually can give the active component of drug regimen with chemical raw material form, but preferably give with Pharmaceutical composition form.Pharmaceutical composition of the present invention comprises EGCG and Folium Bambosae flavone, and the drug regimen of the present invention of one or more pharmaceutically acceptable carriers or excipient.These carriers must be acceptable, can with other component compatibility of formula, and nontoxic to its receiver.When giving separately each component of said composition, they are each form of Pharmaceutical composition naturally generally.Unless otherwise indicated, the compositions of indication of the present invention refers to the drug regimen containing EGCG and Folium Bambosae flavone, or the compositions of the wherein drug regimen of each component of EGCG and Folium Bambosae flavone.
Preferably, the combination of EGCG and Folium Bambosae flavone is generally the Pharmaceutical composition with one or more pharmaceutically acceptable carriers of unit dosage form, and the EGCG contained in conventional unit formulation and the dosage of Folium Bambosae flavone are clear and definite in the foregoing.
Use corresponding, different pharmaceutical carriers and preparation technology, pharmaceutical composition of the present invention can be made different pharmaceutical dosage forms.What those skilled in the art were appreciated that is, these pharmaceutical carriers be become various dosage form for the ease of production and processing, guarantee medicine safe, effectively with the factor such as to stablize, and to select according to the physicochemical property of different pharmaceutical dosage forms and medicine self.The choice for use of pharmaceutical carrier is that those of skill in the art of the present invention know with apparent.
Be to be understood that, for oral or injection, according to method well known in the art, usually according to the pharmaceutical carrier that different medicaments is selected or combinationally used, optionally comprise excipient or diluent, such as microcrystalline Cellulose, mannitol, non-dairy creamer, lactose, pregelatinized Starch, starch, dextrin, cyclodextrin, maltodextrin, HP-β-CD, calcium phosphate, calcium hydrogen phosphate, hydroxypropyl emthylcellulose, sucrose, dextran, poloxamer, sodium chloride, sorbitol, glucose, oligofructose, polyfructosan, oligomeric xylose, polydextrose, Oligomeric manna sugar, solid polyethylene glycol (such as PEG-4000, Polyethylene Glycol-12000, PEG-4000, Polyethylene glycol-2000 etc.), resistant dextrin, fructose, water, propylene glycol, glycerol, coffee, milk powder, vegetable protein powder, etc., for oral solid formulation, optionally can also comprise binding agent, such as polyvidone (polyvinylpyrrolidone), methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, pregelatinized Starch, carboxymethyl starch sodium, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, etc., also comprise lubricant, such as magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate, sodium lauryl sulphate, etc., also optionally comprise disintegrating agent, such as carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, pregelatinized Starch, etc., also optionally comprise surfactant or cosolvent, such as sodium lauryl sulphate, Tween-80, etc., also can comprise pH value regulator or buffer agent or cosolvent, such as phosphate buffer, citric acid, sodium citrate, acetate buffer, dilute hydrochloric acid, lactic acid, sodium carbonate, sodium hydroxide, alkaline organic compound, as arginine, lysine, meglumine, trometamol, etc., also optionally comprise antiseptic, such as sodium benzoate, potassium sorbate, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, etc., also optionally comprise stabilizing agent and antioxidant, such as metal chelating agent selects ethylenediaminetetraacetic acid and salt (calcium disodium edetate, disodium edetate) etc. thereof, sodium sulfite, sodium pyrosulfite, vitamin C, vitamin E, etc., also optionally comprise taste regulator, such as maltose alcohol, fructose, sucrose, saccharin sodium, flavoring orange essence, strawberry essence, etc., that also can comprise other routine in addition, appropriate additive.It is also understood that agent type be tablet or capsule time, can be film coating.For the material of film coating, comprise applicable coating materials, such as hydroxypropyl methylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate (enteric-coating material), etc.; Also can comprise plasticizer, such as Polyethylene Glycol, triethyl citrate, etc.; Also optionally comprise suitable solubilizing agent, as Polyoxyethylene Sorbitan Monooleate; Also can comprise suitable pigment, as titanium dioxide, various ferrum oxide, pink pigment, etc.Should be appreciated that above-mentioned " optionally comprising " refers to namely can optionally choice for use, also can not use.
Especially, the compositions of EGCG of the present invention and Folium Bambosae flavone, EGCG can be different on medicament releasing pattern from the chemical composition of Folium Bambosae flavone, such as EGCG can the form of slow release or controlled release occur, and Folium Bambosae flavone also can the form of slow release or controlled release occur, to improve the not synergism of the blood drug level that EGCG and the time difference of Folium Bambosae flavone in onset or metabolism cause.
In the present patent application, " compositions " refers to described EGCG or/and Folium Bambosae flavone, with other chemical composition, such as, on physiology/mixture that formed of pharmaceutically acceptable carrier or excipient, the object of pharmaceutical composition is conducive to the using of medicine, carries, preserves; " administration " mentioned here refer in order to prevent or disease therapy and to organism (comprising patient or healthy population) deliver described in compound, its pharmaceutically useful salt or its solvate; Described " per unit preparation " refers to the preparation unit of minimum package or minimum form of medication, as each bottle of oral administration solution, each capsules, each tablet or pill, each bag of granule or powder, each injection or injection, each bottle of injection or injection, each piece of suppository, each bottle of eye drop, each pipe ointment, etc.
On the other hand; have now found that; when EGCG and Folium Bambosae flavone combinationally use; it demonstrates unexpected advantage; especially this drug regimen demonstrate outstanding, beyond thought in protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia etc. in synergism, and there is the risk etc. that myocardial infarction, apoplexy or cardiovascular disease cause there is good synergistic function reducing.Preferably; the pharmaceutical composition of EGCG of the present invention and Folium Bambosae flavone; for the preparation of protecting cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia, the application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs, etc.
Therefore, on the other hand, the invention provides a kind of protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia, or reduce the pharmaceutical composition that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs, it contains EGCG and Folium Bambosae flavone.It will be appreciated by those skilled in the art that, in its pharmaceutical composition, the dosage ratio in the compound mode of EGCG and Folium Bambosae flavone, per unit preparation and content, just the same with the aforesaid content of the present invention.
Further, present invention also offers the preparation method of the pharmaceutical composition of EGCG and Folium Bambosae flavone, it comprises and EGCG and Folium Bambosae flavone is mixed with pharmaceutically acceptable pharmaceutical carrier and make acceptable any pharmaceutical preparation on pharmaceutics, such as EGCG and Folium Bambosae flavone and pharmaceutical carrier dry powder blend, dry granulation mixing (dry granulating machine process), wet granulation mixing (with water or alcoholic solution wet granulation), liquid or semisolid mixes (as the content of soft capsule, drop pill dropping liquid mixes) etc., preferred pharmaceutical dosage form is that tablet (comprises dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet etc.), hard capsule (comprising enteric coated capsule), granule, dry suspension, oral solution, dry syrup, powder, oral administration mixed suspension, soft capsule, pill, pellet (comprising enteric coated micropill), drop pill, and oral rapid release or the dosage form such as slow release or controlled release, powder ampoule agent for injection (comprises Injectable sterile fill powder, lyophilized injectable powder), aqueous solution injection, injection can also be with glucose, sodium chloride, fructose, Nulomoline, xylitol or maltose etc. use the aqueous solution of (comprising intravenous injection and intravenous drip) as the intravenous injection of osmotic pressure regulator, also can be the rapid releases of above various dosage form, slow release, the dosage forms such as controlled release, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, born of the same parents rise granule, etc.Especially, by means known in the art preparation, be preferred for preparing tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), oral solution, injection (comprising powder ampoule agent for injection and injection) etc. that pharmaceutics uses; Or
The preparation method of the pharmaceutical composition of the EGCG that the present invention also provides and Folium Bambosae flavone, it comprises EGCG and Folium Bambosae flavone is mixed and made into independent pharmaceutical preparation with pharmaceutically acceptable pharmaceutical carrier respectively, and by two kinds of independent pharmaceutical preparation packages in same medicine box, preferred pharmaceutical dosage form is that tablet (comprises dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet etc.), hard capsule (comprising enteric coated capsule), granule, dry suspension, dry syrup, powder, soft capsule, oral solution, pill, pellet (comprising enteric coated micropill), drop pill, oral administration mixed suspension, and oral rapid release or the dosage form such as slow release or controlled release, powder ampoule agent for injection (comprises Injectable sterile fill powder, lyophilized injectable powder), aqueous solution injection, injection can also be with glucose, sodium chloride, fructose, Nulomoline, xylitol or maltose etc. use the aqueous solution of (comprising intravenous injection and intravenous drip) as the intravenous injection of osmotic pressure regulator.Also can be the dosage form such as rapid release, slow release, controlled release of above various dosage form, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, effervescent granule, etc.Especially, by means known in the art preparation, be preferred for preparing tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), oral solution, injection (comprising powder ampoule agent for injection and injection) etc. that pharmaceutics uses.
Preferably, the invention provides a kind of granule containing EGCG and Folium Bambosae flavone, described EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.2 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.3 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.4 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.5 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.6 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.7 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.8 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1.9) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.15 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1.4) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1.3) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1.2) with weight ratio: the ratio combination of 1;
Concrete, such as preferably EGCG and Folium Bambosae flavone take weight ratio as 0.05:1,0.06:1,0.07:1,0.08:1,0.09:1,0.1:1,0.2:1,0.3:1,0.4:1,0.5:1,0.6:1,0.7:1,0.8:1,0.9:1,1:1,1.1:1,1.2:1,1.3:1,1.4:1,1.5:1,1.6:1,1.7:1,1.8:1,1.9:1,2:1, etc.;
Also containing granule adjuvant in described granule composite, described granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline (i.e. the equal amount of mixture of glucose and fructose), glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol (such as PEG-4000, Polyethylene Glycol-12000, PEG-4000, Polyethylene glycol-2000 etc.), dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, wherein the content of granule adjuvant is greater than 30% with mass ratio range, and the content of preferred particulates agent adjuvant is greater than 45% with mass ratio range, and the content of preferred particulates agent adjuvant is greater than 60% with mass ratio range,
Further, the invention provides a kind of preparation method containing the granule of EGCG and Folium Bambosae flavone, it comprises: EGCG, Folium Bambosae flavone are mixed homogeneously with granule adjuvant respectively, use ethanol water wet granulation again, dry, granulate, wherein the content of granule adjuvant is greater than 30% with mass ratio range; Especially, the invention provides a kind of preparation method containing EGCG and Folium Bambosae flavone granule, it comprises:
(1) prepare burden: take EGCG, Folium Bambosae flavone by formula, first EGCG is added mix homogeneously in granule adjuvant, then add Folium Bambosae flavone mix homogeneously, preferably adopt equal increments hybrid mode to carry out mix homogeneously;
(2) granulate: by the material 75% alcoholic solution soft material prepared in (1), wet granulation, 45 ~ 70 DEG C of dryings, granulate;
(3) pack, check, obtain the granule that the present invention contains EGCG and Folium Bambosae flavone.
Further, above-mentioned granule fill can be obtained capsule in Capsules shell, or above-mentioned granule is pressed into tablet by tablet forming technique.
Further, the present invention also provides the compositions application below of EGCG and Folium Bambosae flavone:
Preparation protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia;
Synergism in waiting, Yi Ji
Application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs, etc.
The compositions of EGCG of the present invention and Folium Bambosae flavone, has the advantage of following three aspects:
1, Folium Bambosae flavone has special taste, is similar to the slight bitterness of Chinese medicine and has back sugariness, can improve the bitter taste of EGCG well, makes oral person be easy to accept;
3, the compositions of EGCG and Folium Bambosae flavone protecting cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve synergism in cardiac-cerebral ischemia etc.; and occur to there is good synergistic function, for comparatively comprehensively preventing and treating cardiovascular and cerebrovascular disease advantageously in the risk that causes of myocardial infarction, apoplexy or cardiovascular disease etc. reducing.
detailed description of the inventionin implementation process of the present invention, those of ordinary skill in the art are not departing from the scope of the present invention various embodiment that the basis with spirit produces and are modifying apparent and be easily carry out.By the following examples application of the present invention etc. done and illustrate further, but do not represent embodiment limitation of the present invention.
The compound tablet of embodiment 1, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 5% ~ 25%, is preferably 15%,
Folium Bambosae flavone 10% ~ 40%, is preferably 30%,
Mannitol 20% ~ 35%, is preferably 30%,
Calcium hydrogen phosphate 8% ~ 20%, is preferably 17%,
Carboxymethyl starch sodium 1% ~ 10%, is preferably 5%,
Hydroxypropyl cellulose aqueous solution is appropriate, and preferably 2.5% hydroxypropyl cellulose aqueous solution, counts 2% with hydroxypropyl cellulose,
Magnesium stearate 0.5% ~ 2%, is preferably 1%;
Its preparation method comprises: by EGCG, Folium Bambosae flavone, mannitol, calcium hydrogen phosphate, carboxymethyl starch sodium crosses 80 mesh sieves respectively, preferred mistake 100 order, after taking by recipe quantity, first by EGCG and mannitol mix homogeneously, obtain A mixed-powder, another by Folium Bambosae flavone and calcium hydrogen phosphate mix homogeneously, obtain B mixed-powder, then by A mixed-powder, after B mixed-powder is mixed homogeneously with carboxymethyl starch sodium, add 2.5% hydroxypropyl cellulose aqueous solution and make soft material, cross 24 mesh sieves to granulate, after 45 ~ 60 DEG C of dryings, 20 mesh sieve granulate, add the magnesium stearate of recipe quantity, mixing, tabletting, obtain.
The compound granule of embodiment 2, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 1% ~ 10%, is preferably 3%,
Folium Bambosae flavone 1% ~ 20%, is preferably 10%,
Granule adjuvant 85% ~ 98%, is preferably fructose 87%;
Wherein said granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline (i.e. the equal amount of mixture of glucose and fructose), glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol (such as PEG-4000, Polyethylene Glycol-12000, PEG-4000, Polyethylene glycol-2000 etc.), dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, most preferably be fructose or/and oligofructose, polyfructosan,
Its preparation method comprises: EGCG, Folium Bambosae flavone, granule adjuvant are crossed 80 mesh sieves respectively, preferred mistake 100 order, after taking by recipe quantity, first EGCG is mixed homogeneously with granule adjuvant, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.Further, above-mentioned granule fill can be obtained capsule in Capsules shell, or above-mentioned granule is pressed into tablet by tablet forming technique.
The compound capsule of embodiment 3, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 10% ~ 30%, is preferably 15%,
Folium Bambosae flavone 15% ~ 45%, is preferably 40%,
Mannitol 15% ~ 35%, is preferably 26%,
Pregelatinized Starch 8% ~ 25%, is preferably 12%,
Carboxymethyl starch sodium 1% ~ 15%, is preferably 5%,
The alcoholic solution of polyvinylpyrrolidone is appropriate, preferably with polyvinylpyrrolidone for 1%,
Magnesium stearate 0.5% ~ 2%, is preferably 1%;
Its preparation method comprises: EGCG, Folium Bambosae flavone, mannitol, pregelatinized Starch, carboxymethyl starch sodium are crossed 80 mesh sieves respectively, and preferred mistake 100 mesh sieve, after taking, first by EGCG and Folium Bambosae flavone mix homogeneously, obtains A mixed-powder by recipe quantity, stand-by; Another by mannitol, pregelatinized Starch, carboxymethyl starch sodium mix homogeneously, obtain B mixed-powder, then A mixed-powder is fully mixed homogeneously with B mixed-powder, the alcoholic solution adding polyvinylpyrrolidone makes soft material, crosses 20 mesh sieves and granulates, 45 ~ 70 DEG C of oven dry, dry granule crosses 18 mesh sieve granulate, add magnesium stearate mix homogeneously, be filled to capsulae vacuus, to obtain final product.
The compound granule of embodiment 4, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 1% ~ 6%, is preferably 2%,
Folium Bambosae flavone 1% ~ 10%, is preferably 8%,
Maltodextrin 3% ~ 10%, is preferably 5%,
Other granule adjuvant 75% ~ 95%, is preferably fructose 85%;
Other granule adjuvant wherein said comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline (i.e. the equal amount of mixture of glucose and fructose), glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, most preferably be fructose or/and oligofructose, polyfructosan,
Its preparation method comprises: EGCG, Folium Bambosae flavone, maltodextrin, other granule adjuvant are crossed 80 mesh sieves respectively, preferred mistake 100 order, after taking by recipe quantity, first EGCG is mixed homogeneously with maltodextrin, other granule adjuvant successively, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.
The compositions of embodiment 5, EGCG and Folium Bambosae flavone is improving the effect in myocardial ischemia
Animal: SD rat, male and female half and half, body weight 160 ~ 190g.
Myocardial infarction and ischemia model: get rat urethane intraperitoneal injection of anesthesia, lie on the back and be fixed on operating-table, expose trachea, open front and plug in respirator, on the left of breastbone, 3,4 rib places open breast, expose heart, with operation needle threading ligation left coronary artery between left auricle root and pulmonary artery circular cone, close thoracic cavity, form myocardial infarction and ischemia model.
Experimental technique: rat is divided into model control group at random, administration group, wherein administration group gives oral administration gavage EGCG 6mg/kg respectively on normal feed basis, Folium Bambosae flavone 12mg/kg, the compositions l0mg/kg of EGCG and Folium Bambosae flavone weight ratio 1:2, each administration group successive administration is after 3 days, myocardial infarction and ischemia model is carried out in the 4th day, oral administration gavage EGCG 6mg/kg is given respectively after modeling success, Folium Bambosae flavone 12mg/kg, the compositions l2mg/kg of EGCG and Folium Bambosae flavone (weight ratio 1:2), 180min after administration, take off heart immediately, with normal saline flushing, weigh heavy (g) whole-heartedly, atrium and each trunk is cut off along coronary sulcus, satisfactory room heavy (g), ventricle is placed in after refrigerator and cooled freezes, below heart ligature, be parallel to arteria coronaria ditch and be cut into 5 by cross-section for ventricular section equably, the thick about 1 ~ 2mm of every sheet, the weight of 5 is the weight (g) of pricking inferior segment, then nitro blue tetrazolium (N-BT) dye liquor is placed in, take out after constant temperature dyeing 15min in 37 DEG C of water baths, normal myocardium dye is skipper, infarcted region cardiac muscle is then not painted or light yellow.Draw the infarcted region on every sheet cardiac muscle two sides, non-infarcted region and cavity scope.Use paper-cut method, measure every sheet cardiac muscle infarcted region on two sides and the weight (mg) of normal myocardium, the gross weight weighing up 5 is ventricle gross weight (mg).Calculate the myocardial infarction percentage ratio (%) of infarcted region, ventricle group infarcted region, bundle inferior segment infarcted region whole-heartedly respectively, compare between group with t inspection, the results are shown in Table 1.
The compositions of table 1 EGCG and Folium Bambosae flavone is on the impact of rats with myocardial ischemia myocardial infarct size
(
,%,n=8)
Conclusion: the compositions of EGCG of the present invention and Folium Bambosae flavone, in the animal model of SD myocardial ischemia in rats, significantly can reduce infarct size, shows good improvement myocardial ischemia, the effect of protecting myocardial cell; Relative to model control group, the compositions group of EGCG and Folium Bambosae flavone has highly significant difference, p<0.01; Relative to Folium Bambosae flavone group and EGCG group, also there is very significant difference, p<0.05.Demonstrate pharmaceutical composition of the present invention at the outstanding role improving myocardial ischemia, protecting myocardial cell.
The compositions of embodiment 6, EGCG and Folium Bambosae flavone is to the protective effect of cerebral ischemia-reperfusion neural cell injury
Employing is closed folder middle cerebral artery and is made specific region, local acute cerebral ischemia in rats model; calculate dead neuronal cell number; observe neuronic morphological change, from the compositions of cell and Molecular level study EGCG and Folium Bambosae flavone in neuroprotective unit and the effect preventing and treating cerebral ischemia.
Method: Wistar rat, body weight 150 ~ 200g, male and female half and half, random packet, is divided into model group, EGCG administration group, Folium Bambosae flavone administration group, EGCG and Folium Bambosae flavone compositions administration group, often organizes 8.
First to rats underwent 10% chloral hydrate anesthesia (ip, 350mg.Kg
-1) after, carefully pry open skull with apparatus, expose and close folder middle cerebral artery and cause specific region, local acute cerebral ischemia model, to close folder middle cerebral artery side for ischemia side (experimental group), opposite side does not close folder (matched group) in contrast.
Each group of equal capable intraperitoneal injection drug of 30min before ischemia.All specimen all have drawn from representational relevant range, and fix through 4% neutral formalin rapidly, conventional dehydration, paraffin embedding, HE dyeing and HSP70 dyeing.Occur karyopycnosis with neuronal cell, karyorrhexis after HE dyeing, karyolysis person is judged to neuronal death, gets 5 high power lens visuals field often opening in section, and statistics dead cell accounts for the percentage ratio of total cell, gets its meansigma methods.
HSP70 is the one in HSP family, and molecular weight is 70KDa, and its major function is that protection is various stress caused cell injury and apoptosis, and induction HSP70 high expressed can alleviate the neuronal damage caused by cerebral ischemia.
Experiment grouping:
(1) model group: intraperitoneal injection equal-volume distilled water;
(3) EGCG administration group: the isopyknic EGCG distilled water solution of intraperitoneal injection, EGCG dosage 5mg/kg;
(4) Folium Bambosae flavone administration group: the isopyknic Folium Bambosae flavone distilled water solution of intraperitoneal injection, Folium Bambosae flavone dosage 12mg/kg;
(5) EGCG and Folium Bambosae flavone compositions administration group: the distilled water solution of the isopyknic EGCG of intraperitoneal injection and Folium Bambosae flavone compositions (weight ratio 1:2.4), EGCG and Folium Bambosae flavone compositions dosage 12mg/kg.
Result: in table 2.
The compositions of table 2 EGCG and Folium Bambosae flavone changes cerebral morphology, the expression (n=8) of nerve cell death rate and HSP70
As can be seen from Table 2; the compositions of EGCG and Folium Bambosae flavone has good protective effect for rat cerebral ischemia; and protection cerebral tissue, neuroprotective cell, alleviate cerebral tissue edema degree; in nerve cell death rate, HSP70 expression data; compared with independent EGCG administration group, Folium Bambosae flavone administration group; there is significant difference, p<0.05.Show the present composition in the effect protecting cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia, protect heart and brain cell.
The compositions of embodiment 7, EGCG and Folium Bambosae flavone is to the effect of bitter taste improving EGCG
Get EGCG and Folium Bambosae flavone weight ratio is the compositions of 1:0.5,1:1,1:1.5,1:2, carry out bitter taste and compare.
The preparation of bitter taste reference material: be the former powder of EGCG and the mixed uniformly powder of maltodextrin of 0,10%, 30%, 50%, 70%, 90% respectively with the addition of maltodextrin, respectively get 5g, add 45 DEG C of hot water of 100ml, abundant dissolving, tastes, obtains the bitter taste reference material that bitter taste degree is labeled as 10.0 points, 9.0 points, 7.0 points, 5.0 points, 3.0 points, 1.0 points respectively, be up to 10.0 points, retain an arithmetic point, score value is higher, characterizes bitter taste larger.
Bitter taste comparative approach: based on bitter taste reference material, by the trial test method of 5 people to testing combination bitter taste, compare with bitter taste reference material, differentiate, testing combination bitter taste is given a mark and (is up to 10.0 points, retain an arithmetic point), average, be used for comparing, the bitter taste of compositions relatively more prepared respectively.
Bitter taste compares the following table 3 of data.
Table 3
As can be seen from 3 tables, the compositions of EGCG of the present invention and Folium Bambosae flavone, compare with the former powder of EGCG, bitter taste significantly declines, and along with the increase of Folium Bambosae flavone content in the composition, the decline of its bitter taste is more; EGCG and Folium Bambosae flavone weight ratio are the compositions of 1:0.5,1:1, its bitter taste only has about 60 percent (p<0.05) of the former powder of EGCG, EGCG and Folium Bambosae flavone weight ratio are the compositions of 1:1.5,1:2, and its bitter taste is all less than 50 percent (p<0.01) of the former powder of EGCG; Demonstrate the present composition, to the bitter taste improving EGCG, there is remarkable effect.
The application in following of the compositions of embodiment 8, EGCG described in embodiment 1 to embodiment 4 and Folium Bambosae flavone:
Preparation protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia;
Application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs.
Claims (10)
1. contain the pharmaceutical composition of EGCG and Folium Bambosae flavone, the dosage form of described medicine is any pharmaceutical dosage form of acceptable on pharmaceutics, its compound mode comprises: EGCG and Folium Bambosae flavone are made compound preparation, or EGCG and Folium Bambosae flavone are made independent preparation respectively, and two kinds of independent preparations are packaged in same drug package assembly.
2. contain the pharmaceutical composition of EGCG and Folium Bambosae flavone, wherein said EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1.
The pharmaceutical composition of 3.EGCG and Folium Bambosae flavone, wherein contain 50 ~ 1000mgEGCG and 50 ~ 2000mg Folium Bambosae flavone in per unit preparation, described " per unit preparation " refers to the preparation unit of minimum package or minimum form of medication, comprises each seed lac wafer, each tablet or pill, each bag of granule or powder, each bottle of oral administration solution, each injection or injection, each bottle of injection or injection, each piece of suppository, each bottle of eye drop, each pipe ointment.
4. the pharmaceutical composition preparation method containing EGCG and Folium Bambosae flavone that described in claim 1 to claim 3, any one contains, it comprises and EGCG and Folium Bambosae flavone is mixed with pharmaceutically acceptable pharmaceutical carrier and make acceptable any pharmaceutical preparation on pharmaceutics.
5. one kind contains the granule of EGCG and Folium Bambosae flavone, described EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1, also containing granule adjuvant in described granule composite, wherein granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline, glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, wherein the content of granule adjuvant is greater than 30% with mass ratio range, the preparation method of described granule comprises:
(1) prepare burden: take EGCG, Folium Bambosae flavone by formula, first EGCG is added mix homogeneously in granule adjuvant, then add Folium Bambosae flavone mix homogeneously;
(2) granulate: by the material 75% alcoholic solution soft material prepared in (1), wet granulation, 45 ~ 70 DEG C of dryings, granulate;
(3) pack, check, to obtain final product.
6. a compound tablet for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 5%~25%,
Folium Bambosae flavone 10% ~ 40%,
Mannitol 20% ~ 35%,
Calcium hydrogen phosphate 8% ~ 20%,
Carboxymethyl starch sodium 1% ~ 10%,
Hydroxypropyl cellulose aqueous solution is appropriate,
Magnesium stearate 0.5% ~ 2%;
Its preparation method comprises: by EGCG, Folium Bambosae flavone, mannitol, calcium hydrogen phosphate, carboxymethyl starch sodium crosses 80 mesh sieves respectively, after taking by recipe quantity, first by EGCG and mannitol mix homogeneously, obtain A mixed-powder, another by Folium Bambosae flavone and calcium hydrogen phosphate mix homogeneously, obtain B mixed-powder, then by A mixed-powder, after B mixed-powder is mixed homogeneously with carboxymethyl starch sodium, add 2.5% hydroxypropyl cellulose aqueous solution and make soft material, cross 24 mesh sieves to granulate, after 45 ~ 60 DEG C of dryings, 20 mesh sieve granulate, add the magnesium stearate of recipe quantity, mixing, tabletting, obtain.
7. a compound granule for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 1%~10%
Folium Bambosae flavone 1% ~ 20%,
Granule adjuvant 85% ~ 98%;
Wherein said granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline, glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, its preparation method comprises: EGCG, Folium Bambosae flavone, granule adjuvant are crossed 80 mesh sieves respectively, after taking by recipe quantity, first EGCG is mixed homogeneously with granule adjuvant, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.
8. a compound capsule for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 10%~30%,
Folium Bambosae flavone 15% ~ 45%,
Mannitol 15% ~ 35%,
Pregelatinized Starch 8% ~ 25%,
Carboxymethyl starch sodium 1% ~ 15%,
The alcoholic solution of polyvinylpyrrolidone is appropriate,
Magnesium stearate 0.5% ~ 2%;
Its preparation method comprises: EGCG, Folium Bambosae flavone, mannitol, pregelatinized Starch, carboxymethyl starch sodium are crossed 80 mesh sieves respectively, after taking, first by EGCG and Folium Bambosae flavone mix homogeneously, obtains A mixed-powder by recipe quantity, stand-by; Another by mannitol, pregelatinized Starch, carboxymethyl starch sodium mix homogeneously, obtain B mixed-powder, then A mixed-powder is fully mixed homogeneously with B mixed-powder, the alcoholic solution adding polyvinylpyrrolidone makes soft material, crosses 20 mesh sieves and granulates, 45 ~ 70 DEG C of oven dry, dry granule crosses 18 mesh sieve granulate, add magnesium stearate mix homogeneously, be filled to capsulae vacuus, to obtain final product.
9. a compound granule for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 1%~6%,
Folium Bambosae flavone 1% ~ 10%,
Maltodextrin 3% ~ 10%,
Other granule adjuvant 75% ~ 95%;
Other granule adjuvant wherein said comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline, glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, its preparation method comprises: EGCG, Folium Bambosae flavone, maltodextrin, other granule adjuvant are crossed 80 mesh sieves respectively, after taking by recipe quantity, first EGCG is mixed homogeneously with maltodextrin, other granule adjuvant successively, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.
10. any one described in claim 1 to claim 3, claim 5 to claim 9 contain EGCG and Folium Bambosae flavone the application of pharmaceutical composition in following:
Preparation protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia;
Application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510228678.XA CN104825873B (en) | 2015-05-07 | 2015-05-07 | Composition of EGCG and bamboo-leaves flavones and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510228678.XA CN104825873B (en) | 2015-05-07 | 2015-05-07 | Composition of EGCG and bamboo-leaves flavones and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104825873A true CN104825873A (en) | 2015-08-12 |
CN104825873B CN104825873B (en) | 2018-06-12 |
Family
ID=53804317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510228678.XA Active CN104825873B (en) | 2015-05-07 | 2015-05-07 | Composition of EGCG and bamboo-leaves flavones and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104825873B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105614869A (en) * | 2016-02-14 | 2016-06-01 | 王保红 | Composition containing Cordyceps militaris and preparation method and application thereof |
CN105831244A (en) * | 2016-03-30 | 2016-08-10 | 浙江科技学院 | Microencapsulation liquid for controlling yoghourt post-acidification and method for controlling yoghourt post-acidification |
CN105962339A (en) * | 2016-05-09 | 2016-09-28 | 山东康富森生物科技有限公司 | Bamboo-leaf flavone catechin tablets and preparation method thereof |
CN108077699A (en) * | 2018-02-07 | 2018-05-29 | 聂聪忠 | A kind of composition and its beverage and preparation method for the nourishing the stomach that sterilizes |
CN108743825A (en) * | 2018-06-28 | 2018-11-06 | 广东南方洁灵科技实业有限公司 | A kind of composition for oral cavity and its preparation method and application containing bamboo-leaves flavones |
CN109315576A (en) * | 2018-10-12 | 2019-02-12 | 肖文中 | Natto bamboo-leaves flavones pressed candy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005082495A (en) * | 2003-09-04 | 2005-03-31 | Pharma Foods International Co Ltd | Cerebral cell-protecting composition |
US20100040696A1 (en) * | 2008-08-12 | 2010-02-18 | Ilse Sente | Composite Particles Having An Antioxidant-Based Protective System, And Topical Compositions Comprising The Same |
CN104587260A (en) * | 2015-01-28 | 2015-05-06 | 福州乾正药业有限公司 | Composition of bamboo leaf flavonoid and chitosan oligosaccharide, as well as preparation method and application thereof |
CN104587266A (en) * | 2015-02-05 | 2015-05-06 | 福州乾正药业有限公司 | Composition of nervonic acid and bamboo leaf flavonoid as well as preparation method and application thereof |
-
2015
- 2015-05-07 CN CN201510228678.XA patent/CN104825873B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005082495A (en) * | 2003-09-04 | 2005-03-31 | Pharma Foods International Co Ltd | Cerebral cell-protecting composition |
US20100040696A1 (en) * | 2008-08-12 | 2010-02-18 | Ilse Sente | Composite Particles Having An Antioxidant-Based Protective System, And Topical Compositions Comprising The Same |
CN104587260A (en) * | 2015-01-28 | 2015-05-06 | 福州乾正药业有限公司 | Composition of bamboo leaf flavonoid and chitosan oligosaccharide, as well as preparation method and application thereof |
CN104587266A (en) * | 2015-02-05 | 2015-05-06 | 福州乾正药业有限公司 | Composition of nervonic acid and bamboo leaf flavonoid as well as preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
葛建等: ""表没食子儿茶素没食子酸酯(EGCG)生物活性研究进展"", 《安徽农业大学学报》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105614869A (en) * | 2016-02-14 | 2016-06-01 | 王保红 | Composition containing Cordyceps militaris and preparation method and application thereof |
CN105831244A (en) * | 2016-03-30 | 2016-08-10 | 浙江科技学院 | Microencapsulation liquid for controlling yoghourt post-acidification and method for controlling yoghourt post-acidification |
CN105831244B (en) * | 2016-03-30 | 2019-09-24 | 浙江科技学院 | A kind of the microencapsulation liquid and control post-acidification of yoghurt method of control post-acidification of yoghurt |
CN105962339A (en) * | 2016-05-09 | 2016-09-28 | 山东康富森生物科技有限公司 | Bamboo-leaf flavone catechin tablets and preparation method thereof |
CN108077699A (en) * | 2018-02-07 | 2018-05-29 | 聂聪忠 | A kind of composition and its beverage and preparation method for the nourishing the stomach that sterilizes |
CN108743825A (en) * | 2018-06-28 | 2018-11-06 | 广东南方洁灵科技实业有限公司 | A kind of composition for oral cavity and its preparation method and application containing bamboo-leaves flavones |
CN109315576A (en) * | 2018-10-12 | 2019-02-12 | 肖文中 | Natto bamboo-leaves flavones pressed candy |
Also Published As
Publication number | Publication date |
---|---|
CN104825873B (en) | 2018-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104825873B (en) | Composition of EGCG and bamboo-leaves flavones and its preparation method and application | |
CN104922145B (en) | Composition of γ-aminobutyric acid and chitosan oligosaccharide and its preparation method and application | |
CN104587260B (en) | The composition of bamboo-leaves flavones and chitosan oligosaccharide, its preparation method and application | |
CN104587266B (en) | The composition of nervonic acid and bamboo-leaves flavones, its preparation method and application | |
CN104739848A (en) | Composition containing L-arabinose and tagatose as well as preparation method and drug application of composition | |
AU2017317950B2 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
CN110327374B (en) | A pharmaceutical composition prepared from maggot for preventing and/or treating convulsion | |
CN104721230A (en) | Composite of milk basic protein and milk mineral, preparation method thereof and application | |
CN104922143B (en) | The composition and its preparation method and application of EGCG and chitosan oligosaccharide | |
CN105326053A (en) | L-carnitine and chitosan oligosaccharide-containing composition and preparation method and application | |
CN104784197A (en) | EGCG and beta-glucan composition, and preparation method, and medical application thereof | |
CN103690955B (en) | Pharmaceutical composition containing ticagrelor and preparation method thereof and medicinal application | |
CN104840800B (en) | Bamboo-leaves flavones and the composition of γ-aminobutyric acid and its preparation method and application | |
CN104825441A (en) | EGCG and gamma-aminobutyric acid composition, and preparation method and applications thereof | |
CN101632659A (en) | Medicinal composition of antiviral medicament and pidotimod, preparation method thereof and medicinal application thereof | |
CN109589323A (en) | Nervonic acid and the solid dispersion composition of EGCG and its preparation method and application | |
CN103735552B (en) | Pharmaceutical composition of ticagrelor and cilostazol and its preparation method and application | |
US7867524B2 (en) | Energizing formulation | |
CN103859395A (en) | Self-emulsifying drug release system of coenzyme Q10 with high absorptivity and preparation method and application thereof | |
CN104739776A (en) | Solid dispersion composition of levocarnitine as well as preparation method and medical application of solid dispersion composition | |
CN103735551B (en) | Pharmaceutical composition of cardiovascular and cerebrovascular vessel and its preparation method and application | |
CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament | |
JPH02152926A (en) | Brain edema depressant | |
WO2016086776A1 (en) | Antifungal compound formulation containing chlorogenic acid and application thereof | |
US20220347121A1 (en) | Methods of preparing compositions containing thymoquinone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231030 Address after: 430000 East Floor, Building C4, Biological Innovation Park, No. 666 Gaoxin Avenue, Handong Lake New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Hubei Chang'e Biological Co.,Ltd. Address before: 350008 Jinshan Industrial Concentration Zone, 6 Lane Road, Jianxin Town, Cangshan District, Fuzhou, Fujian, two, Cangshan, 25. Patentee before: FUZHOU QIANZHENG PHARMACEUTICAL Co.,Ltd. |